Table 1. Alterations of innate immune pathway genes in hematologic malignancies.
| Pathway component | Disease | Alteration | Refs |
|---|---|---|---|
| TLR1, TLR6 |
MDS |
Overexpression |
Wei (2013) |
| TLR2 |
MDS |
Mutation |
Wei (2013) |
| MyD88 |
DLBCL, WM |
Mutation |
Ngo (2011), Trean (2012) |
| |
MDS |
Overexpression |
Wei (2013) |
| IL1RAP |
MDS, AML, CML |
Overexpression |
Barreyro (2012), Askmyr (2013) |
| IRAK1 |
MDS, AML, Melanoma |
Overexpression, activation |
Rhyasen (2013), Srivastava (2012) |
| IRAK3 |
CML |
Overexpression, activation |
del Fresno (2005) |
| IRAK4 |
Melanoma |
Overexpression, activation |
Srivastava (2012) |
| TRAF6 |
MDS |
Overexpression |
Starczynowski (2010) |
| miR-146a | MDS, AML | Deletion | Starczynowski (2010) |
Abbreviations: AML=acute myeloid leukaemia; CML=chronic myeloid leukaemia; DLBCL=diffuse large B-cell lymphoma; MDS=myelodysplastic syndrome; WM=Waldenström's macroglobulinaemia.